probucol has been researched along with Aortic Diseases in 10 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Aortic Diseases: Pathological processes involving any part of the AORTA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Probucol, an agent characterized by lipid-lowering and antioxidant property, retards atherosclerosis effectively." | 7.81 | Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- Mice. ( Dong, Z; Ge, J; Hu, K; Huang, W; Jin, X; Liu, G; Ma, X; Sun, A; Wang, K; Xu, F; Zhao, J; Zhu, H; Zou, Y, 2015) |
| "Probucol, an agent characterized by lipid-lowering and antioxidant property, retards atherosclerosis effectively." | 3.81 | Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- Mice. ( Dong, Z; Ge, J; Hu, K; Huang, W; Jin, X; Liu, G; Ma, X; Sun, A; Wang, K; Xu, F; Zhao, J; Zhu, H; Zou, Y, 2015) |
| " Thus, long-term administration appears to suppress the progression of atherosclerotic vascular disease in this animal model." | 1.30 | Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits. ( Aoki, K; Hori, M; Hoshida, S; Igarashi, J; Kuzuya, T; Yamashita, N, 1997) |
| "3." | 1.28 | Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. ( Daugherty, A; Schonfeld, G; Zweifel, BS, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 6 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, H | 1 |
| Jin, X | 1 |
| Zhao, J | 1 |
| Dong, Z | 1 |
| Ma, X | 1 |
| Xu, F | 1 |
| Huang, W | 1 |
| Liu, G | 1 |
| Zou, Y | 1 |
| Wang, K | 1 |
| Hu, K | 1 |
| Sun, A | 1 |
| Ge, J | 1 |
| Yakushiji, E | 1 |
| Ayaori, M | 1 |
| Nishida, T | 1 |
| Shiotani, K | 1 |
| Takiguchi, S | 1 |
| Nakaya, K | 1 |
| Uto-Kondo, H | 1 |
| Ogura, M | 1 |
| Sasaki, M | 1 |
| Yogo, M | 1 |
| Komatsu, T | 1 |
| Lu, R | 1 |
| Yokoyama, S | 1 |
| Ikewaki, K | 1 |
| Wissler, RW | 1 |
| Vesselinovitch, D | 1 |
| Tomochika, Y | 1 |
| Okuda, F | 1 |
| Tanaka, N | 1 |
| Wasaki, Y | 1 |
| Tokisawa, I | 1 |
| Aoyagi, S | 1 |
| Morikuni, C | 1 |
| Ono, S | 1 |
| Okada, K | 1 |
| Matsuzaki, M | 1 |
| O'Leary, VJ | 1 |
| Tilling, L | 1 |
| Fleetwood, G | 1 |
| Stone, D | 1 |
| Darley-Usmar, V | 1 |
| Hoshida, S | 1 |
| Yamashita, N | 1 |
| Igarashi, J | 1 |
| Aoki, K | 1 |
| Kuzuya, T | 1 |
| Hori, M | 1 |
| Oshima, R | 1 |
| Ikeda, T | 1 |
| Watanabe, K | 1 |
| Itakura, H | 1 |
| Sugiyama, N | 1 |
| Allott, CP | 1 |
| Barry, CD | 1 |
| Bramley, J | 1 |
| John, NW | 1 |
| Mellor, PM | 1 |
| Thomson, DS | 1 |
| Reilly, CF | 1 |
| Ishii, K | 1 |
| Kita, T | 1 |
| Daugherty, A | 1 |
| Zweifel, BS | 1 |
| Schonfeld, G | 1 |
10 other studies available for probucol and Aortic Diseases
| Article | Year |
|---|---|
Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- Mice.
Topics: Animals; Aortic Diseases; Atherosclerosis; Biomarkers; CD11c Antigen; Cells, Cultured; Cholesterol; | 2015 |
Probucol-Oxidized Products, Spiroquinone and Diphenoquinone, Promote Reverse Cholesterol Transport in Mice.
Topics: Androstadienes; Animals; Anticholesteremic Agents; Aorta; Aortic Diseases; Apolipoprotein A-I; Apoli | 2016 |
Combined effects of cholestyramine and probucol on regression of atherosclerosis in rhesus monkey aortas.
Topics: Animals; Aorta; Aortic Diseases; Arteriosclerosis; Cholestyramine Resin; Diet, Atherogenic; Drug The | 1983 |
Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Echocardiograph | 1996 |
The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy.
Topics: Administration, Oral; Animals; Antioxidants; Aortic Diseases; Arteriosclerosis; Blood; Copper; Disea | 1996 |
Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits.
Topics: Administration, Oral; Animals; Antioxidants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Cor | 1997 |
Probucol treatment attenuates the aortic atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
Topics: Actins; Animals; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Arter | 1998 |
Noninvasive 3-D ultrasound of atherosclerotic plaques in the Watanabe rabbit.
Topics: Algorithms; Animals; Anticholesteremic Agents; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; F | 1999 |
[Prevention of atherosclerosis using an antioxidant].
Topics: Animals; Antioxidants; Aortic Diseases; Arteriosclerosis; Cholesterol, LDL; Macrophages; Oxidation-R | 1990 |
Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits.
Topics: Animals; Aorta; Aortic Diseases; Arteriosclerosis; Cholesterol Esters; Cholesterol, Dietary; Diet; L | 1989 |